Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs
publication date: Nov 14, 2022
Guangzhou Lupeng Pharmaceutical completed its second $35 million pre-B tranche led by Kaitai Capital and Temasek. Temasek also led the previous $35 million pre-B tranche, which was completed one year ago. Founded in 2018, Lupeng aims to develop global best-in-class small molecule therapies for cancer, hepatitis B and autoimmune diseases. Currently, the company is conducting nine clinical trials of four clinical stage assets in China and the US. Its lead drug is a selective Bcl-2 inhibitor aimed at advanced leukemia while a second drug, a dual Bcl-2/Bcl-xl inhibitor, also targets cancer. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.